

Current report № 145/2024

Dated December 19, 2024

NOTIFICATION

Sofia, Bulgaria, December 19, 2024 - Pursuant to the requirements of Article 100t of the LPOS and in conjunction with Article 114, par. 9 of the LPOS, "Sopharma" AD (SFA: "Bulgarian Stock Exchange" AD, SPH: Warsaw Stock Exchange) hereby informs, that The Board of Directors, at its meeting held on December 19, 2024, in accordance with the requirements of art. 114, para 2 of the LPOS and in accordance with the Group's strategy for optimization and focus on health related activities, approved the conclusion of the following transaction:

"Sopharma" AD, UIC 831902088, as a seller, to conclude a sales agreement for all shares owned by it in the capital of its subsidiary "Pharmalogistika" AD, UIC: 130959211 with "Sofprint Group" AD, UIC: 175413277 as a buyer.

Interested parties participation:

"Sofprint Group" AD, UIC: 175413277 is an interested party in accordance with art. 114, para 7, item 2 of the LPOS as a subsidiary of "Donev Investments Holding" AD, UIC: 831915121, a shareholder owning over 25% of the capital of "Sopharma" AD.

Transaction Value in accordance with the requirements of art. 114, para 5 of the LPOS:

The total value of the transaction is the market value of BGN 4 391 687.16 according to a market valuation dated December 17, 2024 prepared by an independent appraiser.

Assessment of the applicability conditions under Art. 114, para. 2 of the LPOS:

The value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1, b. b) of the LPOS, but due to the participation of an interested party, it is regulated by art. 114, para. 2 of the LPOS.

Assessment of the applicability under Art. 114, para. 6 of the LPOS:

Regarding this transaction, the hypothesis of Art. 114, para. 6 of the LPOS does not apply.

Ognian Donev

Executive director

Information about the company

"Sopharma" AD

90 years of tradition and modernity - European GMP standards and quality, leader in market cap on the Bulgarian Stock Exchange, good corporate governance practices compliant.

Sopharma produces active pharmaceutical ingredients and medicinal products; conducts activities related to research, development and implementation in the field of phytochemistry, chemistry and pharmaceuticals, provides services related to production and auxiliary activities.

With 9 pharmaceutical plants in the country, including a unique ampoule factory in Bulgaria, the company produces more than 4 billion tablets, 9 million syrup forms, has marketing authorization for over 200 generic products, 15 traditional products, including 12 plant-based for which it uses more than 1500 tons of medicinal plants.

Sopharma has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma consistently invests in new technologies, innovations, research and sustainability. The company maintains a dialogue with all interested parties in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated health related business, that operates in important sectors such as medicinal products' manufacturing, hospital supplies, medicinal products' distribution, retail and many others.